Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640159 · ClinicalTrials.gov registry record · Phase 4
Selegiline to Zelapar Switch Study in Parkinson Disease Patients
A Phase 4 study of Parkinson's Disease, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 48
- Enrollment target
- 5
- Study locations
NCT00640159 is a Phase 4 study of Parkinson's Disease that has completed, run by Baylor College of Medicine. The registered enrollment target is 48 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (93% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT00640159, a Phase 4 study of Parkinson's Disease, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 48 participants
- Enrollment target
- 5
- Study locations
Study Summary
Parkinson's disease (PD) is a progressive neurodegenerative disease. Symptomatic therapy is primarily aimed at restoring dopamine function in the brain. Oral selegiline in conjunction with L-dopa has been a mainstay of therapy for PD patients experiencing motor fluctuations for many years. The mechanisms accounting for selegiline's beneficial adjunctive action in the treatment of PD are not fully understood. Inhibition of monoamine oxidase (MAO) type B (MAO-B) activity is generally considered to be of primary importance. Oral selegiline has low bio-availability and is typically dosed BID, for a total of 5-10 mg daily. Recently, the FDA approved a new orally disintegration tablet (ODT) formulation of selegiline, called ZelaparTM. This new formulation utilizes Zydis technology to dissolve in the mouth, with absorption through the oral mucosa, thereby largely bypassing the gut and avoiding first pass hepatic metabolism. This allows more active drug to be delivered at a lower dose. Consequently, Zelapar is dosed once-daily, up to 2.5 mg per day. There are no empirical data indicating whether the use of the new approved formulation of selegiline ODT (Zelapar) is superior or preferred by patients compared to traditional oral selegiline. It is believed that clinical efficacy will be preserved or enhanced, by delivering more active drug, with improved patient preference for the ODT formulation due to the once-daily dosing . The effectiveness of orally disintegrating selegiline as an adjunct to carbidopa/levodopa in the treatment of PD was established in a multicenter randomized placebo-controlled trial (n=140; 94 received orally disintegrating selegiline, 46 received placebo) of three months' duration. Patients randomized to orally disintegrating selegiline received a daily dose of 1.25 mg for the first 6 weeks and a daily dose of 2.5 mg for the last 6 weeks. Patients were all treated with levodopa and could additionally have been on dopamine agonists, anticholinergics, a
Conditions Studied
Interventions
- DRUG Zelapar
Study Locations (5)
California
- Dee Silver, MD at Coastal Neurological Medical Group, Inc - La Jolla
- James Tetrud, MD at The Parkinson's Institute - Sunnyvale
Texas
- R. Malcolm Stewart, MD at Neurology Specialists of Dallas - Dallas
- PDCMDC 6550 Fannin, Suite 1801 - Houston
Florida
- Stuart Isaacson, MD at Parkinson's Disease and Movement Disorder Center of Boca Raton - Boca Raton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00640159
The ClinicalTrials.gov registry entry for NCT00640159 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (93% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which Zelapar is the first listed.
NCT00640159 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT00640159 about?
NCT00640159 is a clinical study titled "Selegiline to Zelapar Switch Study in Parkinson Disease Patients". Parkinson's disease (PD) is a progressive neurodegenerative disease. Symptomatic therapy is primarily aimed at restoring dopamine function in the brain. Oral selegiline in conjunction with L-dopa has been a mainstay of therapy for PD patients experiencing motor fluctuations for many years. The mecha...
What is the current status of trial NCT00640159?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 2007-01. Estimated completion is 2008-08.
What conditions does trial NCT00640159 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT00640159?
The interventions under investigation include: Zelapar (DRUG).
Who is sponsoring clinical trial NCT00640159?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00640159 being conducted?
This trial has 5 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Validation of Dyskinesia Rating Scales
COMPLETED · Phase 4
-
Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease
COMPLETED · Phase 4
-
Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease
COMPLETED · Phase 4
-
Rasagiline for the Symptomatic Treatment of Fatigue in Parkinson's Disease
COMPLETED · Phase 4
-
Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
COMPLETED · Phase 4
-
Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.